Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JYEST Cell Injection for Prevention of EBV Infection After Allo-HSCT
NCT07476014Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2026
- Primary completion
- Jan 2029
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
01
Overview
Phase 1, open-label, single-arm trial of JYEST cell injection in Epstein-Barr virus infection, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Dose-Limiting Toxicities at 28 days. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
JYEST cell injection
03
Conditions
Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT07476014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476014.